Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 5/20 | 0.47 |
| ▸ | NOS2 | P35228 | 5/20 | 0.47 |
| ▸ | NOS3 | P29474 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 2/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20041146 | 1.00 | NOS1 (0.47) | NOS1NOS2NOS3ALDH1A1SMN1; SMN2 | |
| SCHEMBL20272562 | 0.86 | PLA2G10 (0.50) | NOS1NOS2NOS3ALDH1A1SMN1; SMN2 | |
| SCHEMBL18500970 | 0.86 | SLC7A5 (0.42) | NOS1NOS2NOS3CYP3A4NFKB1 | |
| SCHEMBL27780403 | 0.85 | KDM4E (0.46) | NOS1NOS2NOS3SMN1; SMN2LOXL2 | |
| SCHEMBL2229499 | 0.83 | ADRB2 (0.45) | NOS1NOS2NOS3ALDH1A1SLC7A5 | |
| SCHEMBL5046404 | 0.82 | LOXL2 (0.58) | ALDH1A1LOXL2SLC7A5 | |
| SCHEMBL18402873 | 0.81 | SLC7A5 (0.39) | NOS1NOS2NOS3SLC7A5 | |
| SCHEMBL23643117 | 0.81 | NOS1 (0.47) | NOS1CYP3A4SLC7A5 | |
| SCHEMBL12185043 | 0.81 | LOXL2 (0.45) | NOS1NOS2NOS3ALDH1A1SMN1; SMN2 | |
| SCHEMBL17211514 | 0.81 | GRIA2 (0.50) | CYP3A4NFKB1ENPP2GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | MERCK SHARP & DOHME CORP. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210214395-A1 | PCSK9 ANTAGONISTS BICYCLO-COMPOUNDS | MERCK SHARP & DOHME LLC | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214395-A1 | PCSK9 ANTAGONISTS BICYCLO-COMPOUNDS | PCSK9, PCSK7, PCSK6 | NOS1 2468/4885NOS2 3802/4885NOS3 3270/4885 |
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | PCSK9, PCSK7, PCSK6 | NOS1 2468/4885NOS2 3802/4885NOS3 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.